BioSolar Completes Silicon Anode Lithium-ion Battery Prototypes

March 11, 2020 by Paul Shepard

BioSolar, Inc. announced that its technology partner has completed production and initial testing of the second batch of commercial-grade prototype 21700 lithium-ion cells incorporating additional cell design work. The prototypes will soon be available to potential development partners for their in-house qualification and analysis which will provide critical feedback for the Company as it pursues its battery technology development for electric vehicles.

BioSolar's core focus is developing applications for its performance-boosting additive technology within the high-growth category of silicon anode lithium-ion battery cells.  In this phase of prototype development, BioSolar prepared two different types of commercial grade 21700 cells intended for power tool application. The first was based on the use of silicon alloy anode material comprised of Si micro-particles (Si-MP), and the second on the use of pure silicon anode material comprised of Si nano-particles (Si-NP).

Initial test results for the power and energy capabilities of both types of prototype cells indicate substantial improvement in power and energy capabilities. Based on further comprehensive testing and analysis expected to be performed by potential manufacturing and development partners, the Company will decide further developmental steps and commercialization efforts for each type of material.

You may also like: Samsung Presents Groundbreaking Lithium Metal Solid-State Battery

"We are pleased with the steady progress achieved thus far that has provided our technology partners and leadership with market feedback for the power tool program, as well as a holistic view of our additive technology and its potential role within the electric vehicle category," said Dr. David Lee, Chief Executive Officer of BioSolar.

"The next phase of testing and analysis feedback is especially helpful, as it will likely portray actual market response, meaning we view this as a test of our commercial viability. That said, we understand this is a process that will continue to require fine tuning, of which we will continue disclosing in corporate updates to the public, potential partners and shareholders," concluded Dr. Lee.